TRML (Tourmaline Bio) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Tourmaline Bio's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Tourmaline Bio's long-term debt to total assets ratio declined from Dec. 2023 (0.00) to Dec. 2024 (0.00). It may suggest that Tourmaline Bio is progressively becoming less dependent on debt to grow their business.

Tourmaline Bio LT-Debt-to-Total-Asset Historical Data

The historical data trend for Tourmaline Bio's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio LT-Debt-to-Total-Asset Chart

Tourmaline Bio Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

0.04

Tourmaline Bio Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial							-	-	-	-	-

Tourmaline Bio LT-Debt-to-Total-Asset Calculation

Tourmaline Bio's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0.017	/	309.001
	=

Tourmaline Bio's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0.017	/	309.001
	=

Tourmaline Bio (NAS:TRML) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Tourmaline Bio LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

27 West 24th Street, Suite 702, New York, NY, USA, 10010

Website

https://www.tourmalinebio.com

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.